Biomedical subjects

T J Petrick

Publications and source records attributed to T J Petrick.

5 recordsLinked to original sources

PubMed1983

Double-blind multicenter studies with meclofenamate sodium in the treatment of rheumatoid arthritis in the United States and Canada.

The therapeutic efficacy of N-(2,6-dichloro-m-tolyl)anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) in the management of rheumatoid arthritis was clearly established in four large, double-blind, controlled multicenter studies in 757 patients. In one study, 200 mg/day of meclofenamate sodium was compared with 300 mg/day and placebo for six weeks. Another compared meclofenamate sodium, 300 mg/day, with acetylsalicylic acid (ASA), 3.6 g/day, for eight weeks. Two other long-term studies compared meclofenamate sodium and ASA, 300 mg/day and 3.6 g/day, respectively, for six months; in one, the patients were allowed to receive concomitant gold salts or steroids, while in the other, they were not. Both objective and subjective measures showed that meclofenamate sodium was as effective as ASA and superior to placebo. Gastrointestinal reactions, most commonly diarrhea, were seen more often with meclofenamate sodium than with ASA or placebo, but withdrawal for adverse reactions did not differ significantly between treatment groups. ASA-associated side effects such as tinnitus and deafness were not experienced by the patients receiving meclofenamate sodium. Meclofenamate sodium is a safe, effective agent for the treatment of rheumatoid arthritis.

Adolescent↗

PubMed1983

Multicenter studies in the United States and Canada of meclofenamate sodium in osteoarthritis of the hip and knee. Double-blind comparison with placebo and long-term experience.

N-(2,6-Dichloro-m-tolyl) anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) was compared to placebo in two controlled multicenter trials of similar design, one in 180 patients with osteoarthritis of the hip and the other in 237 patients with osteoarthritis of the knee. Following one week on placebo to establish a baseline, patients were given meclofenamate sodium (300 mg/day) or placebo for a four-week double-blind controlled period of treatment. Improvement with meclofenamate sodium consistently exceeded that with placebo. In the hip and knee trials, the differences were statistically significant for at least three of the four weekly visits in reduction of pain on walking, pain on starting motion, pain on passive motion, night pain (knee only), and tenderness. Early in the study, statistically significant improvement was also observed in tenderness measures of the knee and fabere measures of hip function. At each weekly observation, significantly better global assessment scores of patient condition were reported by the patients (p less than 0.005) and their physicians (p less than 0.01) in the group receiving meclofenamate sodium in both the hip and knee trials. Overall global improvement was reported in 76% of the patients on drug and 42% of those on placebo. 31% of the patients receiving meclofenamate sodium and 23% receiving placebo reported adverse reactions. Gastrointestinal reactions were more frequent among the patients receiving the drug. The improvement achieved during the double-blind phase was maintained or increased in 359 patients who continued into long-term therapy with meclofenamate sodium. Meclofenamate sodium was judged effective and safe in the treatment of osteoarthritis of the hip and knee.

Adult↗

PubMed1980

Control of pain resulting from endodontic therapy: a double-blind, placebo-controlled study.

The efficacy of mefenamic acid, aspirin, and a placebo for control of postendodontic pain was compared in a double-blind, randomized study of 150 patients. Medication was begun immediately prior to the endodontic therapy and continued for a total of eight doses. The results were analyzed in terms of the patients' assessments of postendodontic pain, the need for additional analgesic medication, and the patients' and investigator's evaluations of drug efficacy. The results indicate that mefenamic acid was well tolerated. Mefenamic acid was equal to, or exceeded, aspirin in ability to control postendodontic pain in every comparison made. The converse was never true. Mefenamic acid was statistically superior to placebo in every comparison made. Aspirin was not consistently superior to the placebo. Under the conditions of this trial, it can be stated that, for control of pain following simple endodontic therapy, mefenamic acid rather than aspirin is the drug of choice.

Adolescent↗

PubMed1979

A clinical trial of topically applied 3 percent vidarabine against recurrent herpes labialis.

Seventy-six participants were enrolled in a clinical trial to determine therapeutic effectiveness of 3 percent vidarabine applied topically to recurrent perioral herpetic lesions. Following a 6- to- 12-month natural history phase, a 12-month clinical trial was conducted. Seventy participants developed 463 lesions during 361 episodes. Three percent vidarabine in a water-miscible gel was applied six times daily for 7 days to each lesion in the experimental group. Identically packaged placebo was used by the control group. Group assignment was by computer-generated randomization. Lesion size was reduced when vidarabine, rather than placebo, was applied. The difference was statistically significant (Student's t test, P = 0.02). Vesiculation followed tingling more rapidly when vidarabine, rather than placebo, was applied prior to vesiculation (P = 0.05). No significant difference between the two groups was found in episode frequency or lesion duration. Adverse reactions to vidarabine were not experienced.

Administration, Topical↗

PubMedDate not supplied

Ethics and the reproductive process.

Changes in reproductive technology and contraceptive availability have resulted in ethical reconsiderations in many countries. The United States has been no exception. A discussion of the applicable ethical principles for contraceptive research and family planning programs is presented. Each country must decide its own individual response to a given ethical problem. The paper does not propose solutions but is designed to raise the necessary questions.

Acquired Immunodeficiency Syndrome↗